$3.09
-0.36 (-10.43%)
Open$3.43
Previous Close$3.45
Day High$3.50
Day Low$3.00
52W High$71.50
52W Low$3.12
Volume—
Avg Volume32.3K
Market Cap5.74M
P/E Ratio—
EPS$-41.82
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+204.2% upside
Current
$3.09
$3.09
Target
$9.40
$9.40
$5.45
$9.40 avg
$11.97
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 2.83M | 2.16M | 1.98M |
| Net Income | -84,288,736 | -609,365 | -497,914 |
| Profit Margin | -2,980.4% | -28.2% | -25.1% |
| EBITDA | -83,908,262 | -937,252 | -843,277 |
| Free Cash Flow | — | -606,690 | -515,846 |
| Rev Growth | +100.0% | +2.0% | +14.6% |
| Debt/Equity | — | 0.62 | 0.60 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 35.2 | 28.41B |